If you ever wanted to feel like an insider this is the stock for you [DRTS]

Alpha Tau Medical (DRTS) has one of the best yet somehow unknown stories on the market.

A revolutionary cancer treatment that could **treat all solid tumors even the most high unmet needs like Pancreas and GBM**, with decades of work all coming together, as they have already started submitting Phase 3 data for **FDA approval** and are expecting **PMDA approval** in Japan as well.

But years of progress have gone by with virtually no PR, since the company is **fully financed** and didn’t need the attention.

That led to a community with sharp senses and great hunger for any kind of information, since official news and announcements were few and far apart.

And while all the info is public of course, **following closely became an edge** that is *insider-like*, and I’ll give you some examples.

Just this Monday, the community were the ones who broke the news about the **second successfully treated GBM patient**, by following the doctor leading the U.S. FDA trial.

The last update we got from the company was that the first GBM patient was successfully treated, and walked out of the hospital on his own strength the following day. But thanks to the community we now know a second patient has been treated and they are **“both doing great”**.

Then on Tuesday, the community uncovered that **Blue Owl Capital** has filed a **one million+** position in the company.

That follows the community figuring out **Cathie Wood and ARK** were planning to take a **two million+** position in the stock over **a week prior to it happening(!)**, which came to fruition after many have front run it.

And maybe the most significant find, was a Japanese reporter that attended the **PMDA approval committee**, making it known that the market authorization is all but a formality and a matter of time, which will be turning the clinical-stage pre-revenue company into the potential **commercial oncology platform** it can become.

Even though DRTS already has **55+ clinical sites worldwide**, **FDA Breakthrough Device Designation**, **real life-saving in-human results**, it somehow is stilll under the radar, creating one of the best risk/reward opportunities on the market.

NFA and DYOR, but the word is starting to spread between retail and institutions.